Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sarcoma 27Breast Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Large B-Cell, Diffuse 19Ovarian Neoplasms 14Neoplasms 14Lymphoma 12Burkitt Lymphoma 11Neoplasm Metastasis 10Recurrence 9Lymphoma, Non-Hodgkin 9Triple Negative Breast Neoplasms 8Neuroblastoma 7Fallopian Tube Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia 5Hodgkin Disease 5Unspecified Adult Solid Tumor, Protocol Specific 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma, T-Cell 4Lung Neoplasms 4Liposarcoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4

Interventions

pembrolizumab 10Docetaxel 8senaparib 7Injections 7Capecitabine 7Paclitaxel 6Cisplatin 6Irinotecan 5Fluorouracil 5Leucovorin 4Cyclophosphamide 4Bevacizumab 4tislelizumab 3pertuzumab 3fludarabine 3atezolizumab 3Rifampin 3Oxaliplatin 3Itraconazole 3Gemcitabine 3ontuxizumab 2navoximod 2fluzoparib 2durvalumab 2Trastuzumab 2Nivolumab 2Midazolam 2Hydroxychloroquine 2Carboplatin 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumor × Doxorubicin × Clear all
NCT05661201 2026-03-06

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Georgetown University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡